menu search

BCRX / BioCryst to discontinue development of drug

BioCryst to discontinue development of drug
Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it halted development of BCX9930, which was being tested as a treatment for paroxysmal nocturnal hemoglobinuria and some renal diseases, saying it no longer believes the therapeutic candidate is competitive commercially. BioCryst told investors that discontinuing the BCX9930 program will have a positive financial impact, and research and development expenses in 2023 will be similar to 2022's figures. Read More
Posted: Dec 15 2022, 08:52
Author Name: Market Watch
Views: 103090

BCRX News  

BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?

By Zacks Investment Research
September 19, 2023

BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?

BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revision more_horizontal

BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment

By Proactive Investors
September 18, 2023

BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé more_horizontal

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 3, 2023

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants John Bluth - Investor Re more_horizontal

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

By GlobeNewsWire
May 31, 2023

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will prese more_horizontal

Why BioCryst Pharmaceuticals Stock Is Soaring Today

By The Motley Fool
May 3, 2023

Why BioCryst Pharmaceuticals Stock Is Soaring Today

BioCryst Pharmaceuticals reported first-quarter earnings Wednesday morning. The financial report painted an overall encouraging picture regarding its more_horizontal

BioCryst to Report First Quarter 2023 Financial Results on May 3

By GlobeNewsWire
April 19, 2023

BioCryst to Report First Quarter 2023 Financial Results on May 3

RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will more_horizontal

BioCryst: Good Candidate For Buyout, But Not For Anything Else

By Seeking Alpha
March 8, 2023

BioCryst: Good Candidate For Buyout, But Not For Anything Else

BioCryst Pharmaceuticals, Inc. has one blockbuster potential marketed drug, but not much of a pipeline. Last year, they shelved two separate programs more_horizontal

Why Shares of BioCryst Pharmaceuticals Jumped Today

By The Motley Fool
February 22, 2023

Why Shares of BioCryst Pharmaceuticals Jumped Today

A day after the stock plummeted, it bounced back. more_horizontal


Search within

Pages Search Results: